SHR0410 Injection + SHR0410 Injection + Placebo

Phase 3UNKNOWN

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Postoperative Pain Of Laparoscopic Surgery

Conditions

Postoperative Pain Of Laparoscopic Surgery

Trial Timeline

Jul 1, 2022 → Feb 28, 2023

NCT ID

NCT05459220

About SHR0410 Injection + SHR0410 Injection + Placebo

SHR0410 Injection + SHR0410 Injection + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Postoperative Pain Of Laparoscopic Surgery. The current trial status is unknown. This product is registered under clinical trial identifier NCT05459220. Target conditions include Postoperative Pain Of Laparoscopic Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05459220	Phase 3	UNKNOWN	Jul 1, 2022	Feb 28, 2023	Postoperative Pain Of Laparoscopic Surgery

Competing Products

20 competing products in Postoperative Pain Of Laparoscopic Surgery

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 2	52
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IV	Eisai	Approved	85
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	52
Ondansetron + Palonosetron	Eisai	Phase 2	52
AQUAVAN (fospropofol disodium; GPI 15715 )	Eisai	Phase 2	52
ONO-1101	Ono Pharmaceutical	Phase 2	52
ONO-1101	Ono Pharmaceutical	Phase 2/3	65
Levofloxacin Ophthalmic + Cefuroxime	Santen Pharmaceutical	Phase 1/2	41
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution	Santen Pharmaceutical	Phase 1/2	41
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation	Jiangsu Hengrui Medicine	Phase 1	33
SHR8554 Injection	Jiangsu Hengrui Medicine	Phase 1	33
Esomeprazole	AstraZeneca	Approved	85
deep neuromuscular block	Merck	Pre-clinical	23
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo	Merck	Phase 2	52
MK0966, rofecoxib + Comparator: valdecoxib	Merck	Phase 3	77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, Placebo	Merck	Approved	85
MK0719	Merck	Phase 2	52
Sugammadex + Neostigmine	Merck	Approved	85
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	77
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved